Clinical significance of in vivo cytarabine-induced gene expression signature in AML

References

• Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clinic Proc Mayo Clinic 2006; 81: 247–260.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Pediatr Clin North Am 2008; 55: 21–51, ix.
   PubMed Web of Science ®Google Scholar
• Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905–909.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Rodriguez V, Chang HY, et al. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978; 41: 1610–1622.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15: 875–890.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543–552.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Crews KR, Pounds SB, et al. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 2011; 12: 327–339.
   PubMed Web of Science ®Google Scholar
• Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351: 533–542.
   PubMed Web of Science ®Google Scholar
• Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 3679–3687.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243–252.
   PubMed Web of Science ®Google Scholar
• Pounds S, Cheng C, Cao X, et al. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics 2009; 25: 2013–2019.
   PubMed Web of Science ®Google Scholar
• Jung SH, Owzar K, George SL. A multiple testing procedure to associate gene expression levels with survival. Stat Med 2005; 24: 3077–3088.
   PubMed Web of Science ®Google Scholar
• Pounds S, Cheng C. Robust estimation of the false discovery rate. Bioinformatics 2006; 22: 1979–1987.
   PubMed Web of Science ®Google Scholar
• Konig R, Chiang CY, Tu BP, et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods 2007; 4: 847–849.
   PubMed Web of Science ®Google Scholar
• He W, Dorn DC, Erdjument-Bromage H, et al. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 2006; 125: 929–941.
   PubMed Web of Science ®Google Scholar
• Di Bernardo MC, Broderick P, Harris S, et al. Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation. Leukemia 2013; 27: 255–258.
   PubMed Web of Science ®Google Scholar
• Urayama KY, Thompson PD, Taylor M, et al. Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence. Front Oncol 2013; 3: 300.
   PubMedGoogle Scholar
• Rubnitz JE, Raimondi SC, Halbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia 2002; 16: 2072–2077.
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. Br J Cancer 2004; 91: 707–713.
   PubMed Web of Science ®Google Scholar
• Wu H, Hu C, Wang A, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 2015. [Epub ahead of print]. doi: 10.1038/leu.2015.180.
   Web of Science ®Google Scholar
• Rushworth SA, Murray MY, Zaitseva L, et al. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 2014; 123: 1229–1238.
   PubMed Web of Science ®Google Scholar
• da Costa WH, Rezende M, Carneiro FC, et al. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU Int 2014; 113: E157–E163.
   PubMed Web of Science ®Google Scholar
• Pawlowski R, Muhl SM, Sulser T, et al. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013; 132: E11–E17.
   PubMed Web of Science ®Google Scholar
• Thompson M. Polybromo-1: the chromatin targeting subunit of the PBAF complex. Biochimie 2009; 91: 309–319.
   PubMed Web of Science ®Google Scholar
• Brownlee PM, Chambers AL, Oliver AW, et al. Cancer and the bromodomains of BAF180. Biochem Soc Trans 2012; 40: 364–369.
   PubMed Web of Science ®Google Scholar
• Burrows AE, Smogorzewska A, Elledge SJ. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci USA 2010; 107: 14280–14285.
   PubMed Web of Science ®Google Scholar
• Niimi A, Chambers AL, Downs JA, et al. A role for chromatin remodellers in replication of damaged DNA. Nucleic Acids Res 2012; 40: 7393–7403.
   PubMed Web of Science ®Google Scholar
• Quere R, Saint-Paul L, Carmignac V, et al. Tif1gamma regulates the TGF-beta1 receptor and promotes physiological aging of hematopoietic stem cells. Proc Natl Acad Sci USA 2014; 111: 10592–10597.
   PubMed Web of Science ®Google Scholar
• Kulkarni A, Oza J, Yao M, et al. Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein. J Biol Chem 2013; 288: 32357–32369.
   PubMed Web of Science ®Google Scholar
• Fan Z, Beresford PJ, Oh DY, et al. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003; 112: 659–672.
   PubMed Web of Science ®Google Scholar
• Agarwal A, MacKenzie RJ, Pippa R, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2014; 20: 2092–2103.
   PubMed Web of Science ®Google Scholar
• Stoedter M, Renko K, Ibanez E, et al. Strong induction of iodothyronine deiodinases by chemotherapeutic selenocompounds. Metallomics 2015; 7: 347–354.
   PubMed Web of Science ®Google Scholar